As of October 22, 2026, Bright Minds Biosciences Inc (DRUG) trades at $52.38. No model fair value is published for DRUG. DRUG reports its financial statements in CAD. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — DRUG valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 8 of the last 8 reports. The median share-price change across a report, in either direction, was 2.4%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Aug 14, 2026 | $-1.39 | $-0.17 | +87.8% | +4.0% |
| May 20, 2026 | $-1.26 | $-1.09 | +13.5% | +0.6% |
| Feb 12, 2026 | $-1.18 | $-0.97 | +17.8% | -3.3% |
| Dec 23, 2025 | $-1.00 | $-0.57 | +42.9% | +1.5% |
| Aug 14, 2025 | $-0.88 | $-0.74 | +15.9% | -1.7% |
| May 15, 2025 | $-0.39 | $-0.29 | +25.6% | +2.0% |
| Feb 13, 2025 | $-0.50 | $0.01 | +102.0% | -8.6% |
| Nov 27, 2024 | $-0.60 | $-0.17 | +71.7% | +2.8% |
Equity Rank's fundamental strength composite scores DRUG at 43.1/100 (C-, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved +0.0 over the past 30 days.
DRUG reports its financial statements in CAD. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Bright Minds Biosciences Inc (DRUG) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Bright Minds Biosciences Inc (DRUG) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/DRUG. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.